ES2618802T3 - Composición de rejuvenecimiento cutáneo fotoactivada oxidativa que comprende ácido hialurónico, glucosamina o alantoína - Google Patents

Composición de rejuvenecimiento cutáneo fotoactivada oxidativa que comprende ácido hialurónico, glucosamina o alantoína Download PDF

Info

Publication number
ES2618802T3
ES2618802T3 ES09824320.7T ES09824320T ES2618802T3 ES 2618802 T3 ES2618802 T3 ES 2618802T3 ES 09824320 T ES09824320 T ES 09824320T ES 2618802 T3 ES2618802 T3 ES 2618802T3
Authority
ES
Spain
Prior art keywords
allantoin
glucosamine
skin rejuvenation
hyaluronic acid
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09824320.7T
Other languages
English (en)
Inventor
Remigio Piergallini
Nikolaos Loupis
Francesco Bellini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Klox Technologies Inc
Original Assignee
Klox Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klox Technologies Inc filed Critical Klox Technologies Inc
Application granted granted Critical
Publication of ES2618802T3 publication Critical patent/ES2618802T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/22—Peroxides; Oxygen; Ozone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/732—Starch; Amylose; Amylopectin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/736—Chitin; Chitosan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0616—Skin treatment other than tanning
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/14—Preparations for removing make-up
    • A61Q1/145—Tattoo removal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A61N2005/0663—Coloured light

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physiology (AREA)
  • Environmental Sciences (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Biotechnology (AREA)

Abstract

Una composición de rejuvenecimiento cutáneo que comprende: al menos un oxidante, en el que el oxidante es un peróxido; un fotoactivador capaz de activar al oxidante, en el que el fotoactivador comprende eosina Y; y al menos un factor de cicatrización elegido de ácido hialurónico, glucosamina y alantoína; junto con un vehículo farmacéuticamente aceptable.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
5
10
15
20
25
30
35
40
45
50
55
La inclusión de compuestos fotosensibles adecuados y la activación con una fuente de luz de una longitud de onda adecuada, conduce a la aceleración del proceso de descomposición de la fuente de peróxido (el oxidante) y las otras reacciones que tienen lugar, por medio de un fenómeno fotodinámico. Los colorantes incluidos se iluminan mediante fotones de una cierta longitud de onda y se excitan hasta un estado de energía superior. Cuando los electrones excitados del fotoactivador vuelven a un estado de energía inferior, emiten fotones con un nivel de energía inferior, por lo que se provoca la emisión de luz de una longitud de onda más larga (desplazamiento de Stokes). En el medio adecuado, mucha de esta transferencia de energía se transfiere al oxígeno o al peróxido de hidrógeno reactivo y provoca la formación de radicales de oxígeno, tales como el oxígeno singlete.
Se cree que el oxígeno singlete y otras especies reactivas de oxígeno generadas mediante la activación de la composición funcionan de una manera hormética. Es decir, se provoca un efecto beneficioso para la salud mediante la exposición baja a estímulos normalmente tóxicos (p.ej. oxígeno reactivo), estimulando y modulando las rutas de respuesta al estrés en las células de los tejidos seleccionados como objetivo. La respuesta endógena a los radicales libres generados de manera exógena (especies de oxígeno reactivo) se modula con una capacidad de defensa incrementada contra los radicales libres exógenos, e induce la aceleración de la cicatrización y los procesos regenerativos. Además, la activación de la composición producirá además un efecto antibacteriano. La sensibilidad extrema de las bacterias a la exposición a radicales libres hace de la composición de la presente invención una composición bactericida de facto.
El posible mecanismo de acción debería ser un fenómeno de señalización redox fortalecido que dé como resultado un proceso de transducción de señales acentuado en el que las células conviertan un tipo de señal en otro; los "segundos mensajeros" activados inducen una "cascada de señales" que comienza con un estímulo relativamente pequeño que genera una gran respuesta por medio de una amplificación monitorizada biológicamente de tales señales. Estos mecanismos complejos actúan posiblemente implicando fenómenos angiogénicos por medio de la activación de factores de crecimiento.
Este método se podría describir como una forma de terapia fotodinámica. Sin embargo, a diferencia de otras técnicas fotodinámicas, en las que los fotoactivadores se incorporan en la estructura del tejido, en el presente método, el material fotoactivo está en contacto simple con el tejido y actúa cuando se activa mediante la luz, como un "dispositivo fotodinámico" que interacciona químicamente con el tejido. Además, la luz actínica penetra en el tejido, y la luz que es emitida por el fotoactivador (luz de una longitud de onda más larga) también es absorbida por el tejido.
Se puede usar cualquier fuente de luz actínica. Puede ser adecuado cualquier tipo de lámpara halógena, LED o lámpara de arco voltaico, o láser. La característica principal de las fuentes adecuadas de luz actínica será que emiten luz de una longitud de onda (o longitudes de onda) adecuadas para activar el o los fotoactivadores presentes en la composición. En una realización, se usa un láser de argón. En otra realización, se usa un láser de titanil fosfato de potasio (KTP) (p.ej. un láser GreenLight™). En otra realización, un dispositivo de fotocurado LED es la fuente de luz actínica. En otra realización, la fuente de luz actínica es una fuente de luz visible que tiene una longitud de onda entre 400 y 600 nm. Además, la fuente de luz actínica debería tener una densidad de potencia adecuada. La densidad de potencia adecuada para las fuentes de luz sin colimación (LED, lámparas halógenas o de arco voltaico) están en el intervalo de alrededor de 900 mW/cm2 a alrededor de 2000 mW/cm2. La densidad de potencia adecuada para las fuentes de luz láser están en el intervalo de alrededor de 0,5 mW/cm2 a alrededor de 0,8 mW/cm2.
La duración de la exposición a la luz actínica dependerá de la superficie del área tratada, y del tipo de lesión, traumatismo o herida que se va a tratar. La fotoactivación de la composición puede tener lugar en segundos o incluso en fracciones de segundo, pero un periodo prolongado de exposición es beneficioso para aprovechar el efecto sinérgico de la luz absorbida, reflejada y reemitida en la composición de la presente invención y su interacción con el tejido a tratar. En una realización, el tiempo de exposición a la luz actínica del tejido, piel o herida en la que se ha aplicado la composición de rejuvenecimiento cutáneo es un periodo de entre 60 segundos y 5 minutos. En otra realización, el tiempo de exposición a la luz actínica del tejido, piel o herida en la que se ha aplicado la composición de rejuvenecimiento cutáneo es un periodo de entre 60 segundos y 5 minutos por cm2 del área a tratar, de forma que el tiempo total de exposición de 10 cm2 sería de entre 10 minutos y 50 minutos. En otra realización, la fuente de luz actínica está en continuo movimiento sobre el área tratada durante el tiempo adecuado de exposición. En otra realización, se llevan a cabo múltiples aplicaciones de la composición de rejuvenecimiento cutáneo y de la luz actínica. En ciertas realizaciones, el tejido, piel o herida se expone a la luz actínica al menos dos, tres, cuatro, cinco
o seis veces. En ciertas realizaciones, se da una aplicación nueva de la composición de rejuvenecimiento cutáneo antes de la exposición a la luz actínica.
Ejemplos
EJEMPLO I
Se preparó una composición de rejuvenecimiento cutáneo ejemplar, fuera del alcance de las presentes reivindicaciones, mezclando los siguientes componentes:
9
imagen8
los bordes de la herida. Durante una hora, se colocó una barrera impermeable (p.ej. una lámina de silicona) entre el colgajo y su sitio donante para eliminar la posibilidad de apoyo del lecho de la herida. Después se retiró la lámina, el colgajo volvió a su posición original y los bordes del colgajo se cerraron quirúrgicamente mediante el uso de sutura de nailon 4/0 de una manera discontinua. Inmediatamente tras el cierre del colgajo, se revistió el pedículo del colgajo
5 con 13,5 g de formulación de gel (0,5 g/cm2) y se irradiaron. Los controles no recibieron tratamiento. Se tuvo cuidado de distribuir uniformemente la pomada a lo largo de todo el colgajo. La formulación de gel se preparó el mismo día del experimento. Para el grupo de Gel + Luz, los animales se trataron con la formulación de gel y el colgajo se irradió durante 3 minutos con una lámpara LED.
Con respecto a la Fig. 3, los resultados muestran un grosor dérmico incrementado y la formación de colágeno nuevo
10 en la piel tratada con la composición de la presente invención frente a la piel sin tratar. Este resultado apoya el papel de la composición de la presente invención en la estimulación de mejores resultados en el proceso de rejuvenecimiento cutáneo.
Las realizaciones y ejemplos presentados en la presente memoria son ilustrativos de la naturaleza general de la materia reivindicada, y no son limitantes. Los expertos en la técnica entenderán cómo se pueden modificar 15 fácilmente estas realizaciones y/o adaptarlas para las diversas aplicaciones y de diversas maneras sin apartarse del alcance de la materia reivindicada. Se debe entender que las reivindicaciones del presente documento incluyen sin limitación todas las realizaciones alternativas de la materia del presente documento. Las frases, palabras y términos empleados en la presente memoria son ilustrativos, y no son limitantes. Se apreciará que cualquier aspecto de las diferentes realizaciones descritas en la presente memoria se puede combinar en una diversidad de posibles
20 realizaciones alternativas, todas las cuales se entiende que forman parte de la materia reivindicada.
11

Claims (1)

  1. imagen1
ES09824320.7T 2008-11-07 2009-11-06 Composición de rejuvenecimiento cutáneo fotoactivada oxidativa que comprende ácido hialurónico, glucosamina o alantoína Active ES2618802T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11223508P 2008-11-07 2008-11-07
US112235 2008-11-07
PCT/CA2009/001615 WO2010051641A1 (en) 2008-11-07 2009-11-06 Oxidatitive photoactivated skin rejeuvenation composition comprising hyaluronic acid, glucosamine, or allantoin

Publications (1)

Publication Number Publication Date
ES2618802T3 true ES2618802T3 (es) 2017-06-22

Family

ID=42152429

Family Applications (3)

Application Number Title Priority Date Filing Date
ES09824320.7T Active ES2618802T3 (es) 2008-11-07 2009-11-06 Composición de rejuvenecimiento cutáneo fotoactivada oxidativa que comprende ácido hialurónico, glucosamina o alantoína
ES16199672T Active ES2743314T3 (es) 2008-11-07 2009-11-06 Composición de rejuvenecimiento cutáneo fotoactivada oxidativa
ES09824315.7T Active ES2632717T3 (es) 2008-11-07 2009-11-06 Combinación de un oxidante y un fotoactivador para la cicatrización de heridas

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES16199672T Active ES2743314T3 (es) 2008-11-07 2009-11-06 Composición de rejuvenecimiento cutáneo fotoactivada oxidativa
ES09824315.7T Active ES2632717T3 (es) 2008-11-07 2009-11-06 Combinación de un oxidante y un fotoactivador para la cicatrización de heridas

Country Status (25)

Country Link
US (14) US8658219B2 (es)
EP (4) EP2365829B1 (es)
JP (10) JP5478632B2 (es)
KR (5) KR101835047B1 (es)
CN (4) CN104707143B (es)
AU (2) AU2009311239B2 (es)
BR (2) BRPI0921269A2 (es)
CA (4) CA2742942C (es)
CY (2) CY1118716T1 (es)
DK (3) DK3150210T3 (es)
EA (5) EA024827B1 (es)
ES (3) ES2618802T3 (es)
HK (1) HK1211478A1 (es)
HR (3) HRP20171022T1 (es)
HU (2) HUE032192T2 (es)
IL (4) IL212560A (es)
LT (2) LT2352488T (es)
MX (3) MX337084B (es)
NZ (5) NZ592651A (es)
PL (3) PL2352488T3 (es)
PT (3) PT2352488T (es)
SG (2) SG10201703078QA (es)
SI (2) SI2365829T1 (es)
SM (2) SMT201700155T1 (es)
WO (2) WO2010051636A1 (es)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2861734B1 (fr) 2003-04-10 2006-04-14 Corneal Ind Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus
WO2007080453A2 (en) 2005-11-09 2007-07-19 Klox Technologies Inc. Teeth whitening compositions and methods
US20100266989A1 (en) * 2006-11-09 2010-10-21 Klox Technologies Inc. Teeth whitening compositions and methods
US8114898B2 (en) 2007-11-16 2012-02-14 Allergan, Inc. Compositions and methods for treating purpura
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US8357795B2 (en) 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
AU2009288118B2 (en) 2008-09-02 2014-12-11 Allergan, Inc. Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
PL2352488T3 (pl) 2008-11-07 2017-07-31 Klox Technologies Inc. Utleniająca, aktywowana światłem kompozycja do odmładzania skóry zawierająca kwas hialuronowy, glukozaminę lub alantoinę
AU2014203119B2 (en) * 2009-07-17 2016-06-09 Klox Technologies Inc. Combination of an oxidant, a photosensitizer and a wound healing agent for oral disinfection and treatment of oral disease
HUE035716T2 (en) * 2009-07-17 2018-05-28 Klox Tech Inc Antibacterial oral composition
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
CN102905677A (zh) 2010-03-12 2013-01-30 阿勒根工业有限公司 用于改善皮肤状况的包含透明质烷聚合物和甘露糖醇的流体组合物
ES2585388T5 (es) 2010-03-22 2019-08-08 Allergan Inc Hidrogeles reticulados de polisacárido y proteína-polisacárido para aumento de tejido blando
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
KR102312056B1 (ko) 2011-06-03 2021-10-12 알러간 인더스트리 에스에이에스 항산화제를 포함하는 피부 충전제 조성물
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9662422B2 (en) 2011-09-06 2017-05-30 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US11116841B2 (en) 2012-04-20 2021-09-14 Klox Technologies Inc. Biophotonic compositions, kits and methods
US20130281913A1 (en) 2012-04-20 2013-10-24 Klox Technologies Inc. Biophotonic compositions and methods for providing biophotonic treatment
US10549112B2 (en) 2012-07-20 2020-02-04 The General Hospital Corporation Apparatus for tissue irradiation and methods and kits utilizing the same
WO2014015274A1 (en) * 2012-07-20 2014-01-23 The General Hospital Corporation Methods for tissue passivation
KR20150082189A (ko) 2012-09-14 2015-07-15 밸리언트 파마슈티컬즈 인터내셔널, 인코퍼레이션 치아미백용 조성물 및 치아미백 방법
KR20210072827A (ko) * 2012-09-14 2021-06-17 광동 클록스 바이오메디컬 그룹 씨오., 엘티디 생체 광자성 용도를 위한 발색단 조합
JP2015528473A (ja) * 2012-09-14 2015-09-28 クロックス テクノロジーズ インコーポレイテッドＫｌｏｘ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． 美容生体光組成物
JP6116842B2 (ja) * 2012-09-25 2017-04-19 国立大学法人 東京大学 標的細胞特異的な光増感用化合物。
US20140276354A1 (en) 2013-03-14 2014-09-18 Klox Technologies Inc. Biophotonic materials and uses thereof
CN103432581A (zh) * 2013-03-22 2013-12-11 北京海思威科技有限公司 速立氧注射剂在制备治疗疾病的病毒灭活中的应用
EP2980585B1 (en) * 2013-03-29 2019-11-20 Mie University Vital stain
CN105431515A (zh) 2013-05-24 2016-03-23 宝洁公司 低ph洗涤剂组合物
HK1219890A1 (zh) * 2013-07-03 2017-04-21 广东科洛克生物医药集团有限公司 治疗不癒合伤口的组合物和方法
CA3278502A1 (en) 2013-07-18 2025-10-31 The General Hospital Corporation Vessel treatment systems, methods, and kits
WO2015067594A1 (en) * 2013-11-05 2015-05-14 Nestec S.A. Use of glucosamine-enriched plant compositions
JP2017509433A (ja) 2014-04-01 2017-04-06 クロックス テクノロジーズ インコーポレイテッドＫｌｏｘ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． 組織充填剤組成物および使用方法
AR100864A1 (es) * 2014-06-09 2016-11-09 Klox Tech Inc Composiciones biofotónicas termoendurecibles y sus usos
WO2015189712A2 (en) * 2014-06-09 2015-12-17 Klox Technologies Inc. Silicone-based biophotonic compositions and uses thereof
JP2017519026A (ja) * 2014-06-24 2017-07-13 クロクス テクノロジーズ インコーポレイテッド ハロゲンを含む生体光組成物およびその使用
CA2953260C (fr) * 2014-06-30 2020-09-15 Nutricos Technologies Produits de combinaison et compositions cosmetiques pour lutter contre les desordres de la peau et son vieillissement affectant les keratinocytes et/ou les fibroblastes et le derme
US10016456B2 (en) * 2014-07-18 2018-07-10 Dabney Patents, L.L.C. Methods for treating acne vulgaris
CN106659902A (zh) * 2014-07-18 2017-05-10 保罗·达布尼 对于治疗化合物的光线的人类医疗和兽医应用
WO2016051219A1 (en) 2014-09-30 2016-04-07 Allergan Industrie, Sas Stable hydrogel compositions including additives
ES2856841T3 (es) 2014-10-31 2021-09-28 Klox Tech Inc Fibras y medios de tela fotoactivables
WO2016128783A1 (en) 2015-02-09 2016-08-18 Allergan Industrie Sas Compositions and methods for improving skin appearance
PL3256179T3 (pl) 2015-02-13 2020-05-18 Allergan Industrie, Sas Implanty do kształtowania, uwydatniania lub korygowania cech twarzy takich jak broda
CN105031649A (zh) * 2015-08-27 2015-11-11 厦门大学 一种掺杂自组装纳米纤维结构及其制备方法
KR20180079400A (ko) * 2015-10-30 2018-07-10 데브니 페이턴즈, 엘.엘.씨. 문신의 퇴색 및 제거용 시스템, 장치 및 방법
CN105342915A (zh) * 2015-11-19 2016-02-24 山东朱氏堂医疗器械有限公司 一种光子冷凝胶及其制备方法
BR112018014161A2 (pt) * 2016-01-11 2018-12-11 Klox Tech Limited composições biofotônicas para tratar ferimento de pele e tecido mole tendo uma ou ambas as infecções resistentes e não resistentes
WO2017120672A1 (en) * 2016-01-11 2017-07-20 Klox Technologies Limited Biophotonic compositions for the treatment of pyoderma
US10610513B2 (en) 2016-01-11 2020-04-07 Klox Technologies Limited Biophotonic compositions for the treatment of otitis externa
CN107837209A (zh) * 2016-09-21 2018-03-27 张黎 一种纹绣无痕清洗液
WO2018053646A1 (en) * 2016-09-23 2018-03-29 Klox Technologies Inc. Biophotonic compositions, methods, and kits for inhibiting and disrupting biofilms
JP2018048100A (ja) * 2016-09-23 2018-03-29 クロクス テクノロジーズ インコーポレイテッド 疼痛の軽減のためのバイオフォトンの組成物、方法およびキット
WO2018145208A1 (en) * 2017-02-08 2018-08-16 Klox Technologies Inc. Biophotonic methods for increasing in situ energy production and energy emission in biological cells and tissues
US20200000917A1 (en) * 2017-02-22 2020-01-02 The General Hospital Corporation Methods of photochemical treatment for wound healing
US20210170027A1 (en) * 2017-11-17 2021-06-10 Klox Technologies Limited Biophotonic compositions, methods and kits for enhancing hair growth
RU2699362C2 (ru) * 2018-01-16 2019-09-05 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НОВАСКИН" (ООО "Новаскин") Композиция на основе наночастиц диоксида церия и полисахаридов бурых водорослей для лечения ран
KR102012581B1 (ko) * 2018-01-22 2019-08-20 주식회사 디알나노 메틸렌블루 혼합물을 포함하는 패치형 창상피복재
US10967197B2 (en) 2018-08-29 2021-04-06 Azulite, Inc. Phototherapy devices and methods for treating truncal acne and scars
CN113766832B (zh) * 2019-01-31 2023-01-24 帕尔斯希拉公司 杀菌方法和组合物
CN109999225B (zh) * 2019-04-24 2021-06-08 温州医科大学 一种骨修复材料及其制备方法
JP7405543B2 (ja) * 2019-09-19 2023-12-26 オリザ油化株式会社 経口美肌用組成物
KR102309402B1 (ko) * 2019-12-03 2021-10-07 한국에너지기술연구원 광에너지 방출 물질을 포함하는 시트
US12433964B2 (en) 2020-05-07 2025-10-07 Purdue Research Foundation Antiviral and antibacterial disinfection aero-solution using edible food dyes
RU2753794C1 (ru) * 2021-02-04 2021-08-23 Никита Андреевич Чунихин Способ лечения хронических периодонтитов с применением технологии трансканальной лазерной беспигментной фотоабляции
IT202100014150A1 (it) * 2021-05-31 2022-12-01 Vs Ortho Societa’ A Responsabilita’ Limitata Lampada dentale foto-polimerizzante
CN115054539B (zh) * 2021-08-27 2024-06-18 湖南科洛克医药有限公司 一种消炎祛疤凝胶的制备工艺
CN115054567B (zh) * 2021-08-30 2024-10-01 湖南科洛克医药有限公司 一种皮肤创口修护凝胶及其使用方法和应用
IT202200000689A1 (it) * 2022-01-18 2023-07-18 Marco Balato Impiego di coloranti nell’identificazione selettiva di siti infetti nelle infezioni biofilm correlate
JP7587639B2 (ja) * 2022-10-25 2024-11-20 ロート製薬株式会社 アクネ菌バイオフィルム破壊組成物
CN115487340B (zh) * 2022-10-31 2023-11-17 振德医疗用品股份有限公司 一种负载活性氧的细菌纤维素敷料及其制备方法
CN115957331B (zh) * 2022-12-08 2025-07-11 沈阳药科大学 一种除疤痕凝胶剂及其制备方法

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA495814A (en) * 1953-09-08 H. Gorin Manuel Antiseptic wound dressing
US2877221A (en) 1954-03-17 1959-03-10 Pfizer & Co C 11, 14-peroxides of substituted ergostadiene compounds
US3309274A (en) 1962-07-23 1967-03-14 Brilliant Herbert Use of fluorescent dyes in dental diagnostic methods
US3293127A (en) 1964-07-22 1966-12-20 Gold Crest Chemical Corp Inc Arterial embalming fluid and method for embalming therewith
DE1617744A1 (de) 1964-07-24 1970-09-10 Peter Strong & Co Inc Reinigungsmittel fuer Zahnprothesen
NL152290B (nl) 1965-09-08 1977-02-15 American Cyanamid Co Werkwijze ter bereiding van chemiluminescerende mengsels.
US3372125A (en) 1965-11-15 1968-03-05 Peter Strong & Company Inc Denture cleanser
US3595798A (en) 1967-12-18 1971-07-27 Lever Brothers Ltd Cleansing compositions
US3671450A (en) 1969-09-22 1972-06-20 American Cyanamid Co Chemiluminescent compositions
US3728446A (en) 1971-01-11 1973-04-17 Colgate Palmolive Co Speckled dentifrice gel
FR2463613A1 (fr) 1979-08-20 1981-02-27 Thorel Jean Noel Nouvelles compositions pour la revelation de la plaque dentaire
US4574097A (en) 1984-08-10 1986-03-04 Isopedix Corporation Reinforced thixotropic gel composition
US4846165A (en) 1986-11-26 1989-07-11 Dentsply Research & Development Corp. Wound dressing membrane
JPH01279838A (ja) 1988-04-30 1989-11-10 Kiyuukiyuu Yakuhin Kogyo Kk 塩化リゾチーム含有歯肉炎・歯槽膿漏用貼付剤
US4891211A (en) 1988-06-29 1990-01-02 Church & Dwight Co., Inc. Stable hydrogen peroxide-releasing dentifice
EP0356868A3 (en) 1988-09-01 1991-03-20 Dentsply International, Inc. A method of treating a tooth with adhesive dental cavity basing composition
NL8900165A (nl) 1989-01-24 1990-08-16 Matthijs Cornelis Evers Wondpoeder.
CA2028136A1 (en) 1989-02-28 1990-09-29 Marc N. Benhuri Method and composition for treatment of periodontal disease
JPH0383927A (ja) 1989-08-25 1991-04-09 Sunstar Inc 歯周組織再生促進剤
US4992256A (en) 1989-09-27 1991-02-12 Colgate-Palmolive Company Plaque disclosing compositions
DE4007428A1 (de) * 1990-03-09 1991-09-12 Hoechst Ag Photopolymerisierbares gemisch und daraus hergestelltes aufzeichnungsmaterial
US5800373A (en) 1995-03-23 1998-09-01 Focal, Inc. Initiator priming for improved adherence of gels to substrates
US5749968A (en) 1993-03-01 1998-05-12 Focal, Inc. Device for priming for improved adherence of gels to substrates
US5705357A (en) 1994-08-29 1998-01-06 Johnson & Johnson Clinical Diagnostics, Inc. Chemiluminescent reagent and assay using a substituted acetanilide for light generation
US5599342A (en) * 1995-01-27 1997-02-04 Candela Laser Corporation Method for treating pigmentation abnormalities using pulsed laser radiation with an elongated cross-section and apparatus for providing same
JP4209941B2 (ja) 1995-03-23 2009-01-14 ジェンザイム・コーポレーション ゲルの基材への改善された接着性のための下塗り用のレドックスおよび光開始剤システム
US5658148A (en) * 1995-04-26 1997-08-19 Ceramoptec Industries, Inc. Dental laser brushing or cleaning device
US6056548A (en) 1995-04-26 2000-05-02 Ceramoptec Industries, Inc. Hygienic dental laser photo treatment method
JPH092925A (ja) 1995-06-16 1997-01-07 Shiseido Co Ltd ２剤混合式化粧料
DE69626297T2 (de) 1995-09-25 2003-12-11 Robert Eric Montgomery Zahnbleichende zusammensetzungen
US5713738A (en) 1995-12-12 1998-02-03 Britesmile, Inc. Method for whitening teeth
US6541460B2 (en) * 1996-08-07 2003-04-01 George D. Petito Method for use of hyaluronic acid in wound management
AU4185397A (en) 1996-09-16 1998-04-02 Procter & Gamble Company, The Antimicrobial oral care compositions
US5913884A (en) 1996-09-19 1999-06-22 The General Hospital Corporation Inhibition of fibrosis by photodynamic therapy
US7390668B2 (en) 1996-10-30 2008-06-24 Provectus Pharmatech, Inc. Intracorporeal medicaments for photodynamic treatment of disease
US7353829B1 (en) * 1996-10-30 2008-04-08 Provectus Devicetech, Inc. Methods and apparatus for multi-photon photo-activation of therapeutic agents
US6846182B1 (en) 1996-11-27 2005-01-25 Jeffrey A. Sibner Dental bleaching composition and method
WO1998023219A1 (en) 1996-11-27 1998-06-04 Sibner Jeffrey A Dental bleaching composition and method
US8182473B2 (en) 1999-01-08 2012-05-22 Palomar Medical Technologies Cooling system for a photocosmetic device
FR2756741B1 (fr) * 1996-12-05 1999-01-08 Cird Galderma Utilisation d'un chromophore dans une composition destinee a etre appliquee sur la peau avant un traitement laser
JPH10182390A (ja) 1996-12-25 1998-07-07 Lion Corp 口腔用組成物
US6391283B1 (en) 1997-01-10 2002-05-21 Ultradent Products, Inc. Methods and apparatus for activating dental compositions
US5858332A (en) 1997-01-10 1999-01-12 Ultradent Products, Inc. Dental bleaching compositions with high concentrations of hydrogen peroxide
US5785527A (en) 1997-01-10 1998-07-28 Ultradent Products, Inc. Stable light or heat activated dental bleaching compositions
DK0956280T3 (da) 1997-01-30 2003-02-24 Ciba Sc Holding Ag Ikke-flygtige phenylglyoxylsyreestere
US6305936B1 (en) 1997-02-19 2001-10-23 Ultradent Products, Inc. Polymerizable isolation barriers with reduced polymerization strength and methods for forming and using such barriers
ES2196414T3 (es) 1997-02-24 2003-12-16 Kuraray Co Composicion antimicrobiana para la deteccion de caries.
US5922331A (en) * 1997-03-26 1999-07-13 Chanel, Inc. Skin cream composition
JPH10330235A (ja) 1997-06-02 1998-12-15 Lion Corp 義歯洗浄剤
US6108850A (en) 1997-06-03 2000-08-29 Mclaughlin; Gerald Accelerated method and instrumentation for whitening teeth
US6161544A (en) 1998-01-28 2000-12-19 Keratoform, Inc. Methods for accelerated orthokeratology
US6162055A (en) 1998-02-13 2000-12-19 Britesmile, Inc. Light activated tooth whitening composition and method of using same
ES2308833T3 (es) 1998-02-13 2008-12-01 Britesmile Professional, Llc Composicion de blanqueamiento dental activada por luz y metodo de uso de la misma.
US20030198605A1 (en) 1998-02-13 2003-10-23 Montgomery R. Eric Light-activated tooth whitening composition and method of using same
US6149895A (en) 1998-02-17 2000-11-21 Kreativ, Inc Dental bleaching compositions, kits & methods
US5977199A (en) 1998-02-17 1999-11-02 The Kerr Corporation Composition, delivery system therefor, and method for making temporary crowns and bridges
AU3371799A (en) 1998-03-30 1999-10-18 Fibermark, Inc. Light-activated antimicrobial polymeric materials
US6036493A (en) 1998-07-23 2000-03-14 Ad Dent Inc. Dental bleaching system and method
US7648695B2 (en) 1998-08-06 2010-01-19 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
JP4199333B2 (ja) 1998-08-07 2008-12-17 宇部マテリアルズ株式会社 歯磨組成物
US6887260B1 (en) 1998-11-30 2005-05-03 Light Bioscience, Llc Method and apparatus for acne treatment
US6030222A (en) 1998-12-01 2000-02-29 Tarver; Jeanna G. Dye compositions and methods for whitening teeth using same
US6183773B1 (en) 1999-01-04 2001-02-06 The General Hospital Corporation Targeting of sebaceous follicles as a treatment of sebaceous gland disorders
US6423697B1 (en) 1999-01-14 2002-07-23 Mark Friedman Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache, facial pain, and cervical-muscle spasm
US6420455B1 (en) 1999-06-18 2002-07-16 3M Innovative Properties Company Antimicrobial composition containing photosensitizers articles, and methods of use
IT1306679B1 (it) * 1999-06-29 2001-10-02 Fidia Advanced Biopolymers Srl Uso dei derivati dell'acido ialuronico per la preparazione dicomposizoni farmaceutiche e biomateriali per la prevenzione della
US6365134B1 (en) 1999-07-07 2002-04-02 Scientific Pharmaceuticals, Inc. Process and composition for high efficacy teeth whitening
NL1012696C2 (nl) 1999-07-23 2001-01-24 Berg Electronics Mfg Stekker of contrastekker voor gebruik in een voedingsconnector.
JP5689573B2 (ja) * 1999-08-13 2015-03-25 プロヴェクタス ファーマテック，インク． 疾患の光線力学的療法のための改良された局所用薬品および方法
US7220438B2 (en) 1999-09-23 2007-05-22 Asac Compañia de Biotecnologia Pharmacological activities of Curcuma longa extracts
US6475497B1 (en) 1999-12-08 2002-11-05 The Procter & Gamble Company Tartar control denture adhesive compositions
US6905672B2 (en) 1999-12-08 2005-06-14 The Procter & Gamble Company Compositions and methods to inhibit tartar and microbes using denture adhesive compositions with colorants
US6475498B1 (en) 1999-12-08 2002-11-05 The Procter & Gamble Company Method to inhibit tartar and stain using denture adhesive compositions
DE60015790T2 (de) 1999-12-08 2005-11-03 The Procter & Gamble Company, Cincinnati Zahnprothesenhaftmittel zur kontrolle der zahnsteinbildung
US6444725B1 (en) 2000-01-21 2002-09-03 3M Innovative Properties Company Color-changing dental compositions
JP4271339B2 (ja) 2000-03-31 2009-06-03 富士フイルム株式会社 サーマルヘッドの製造方法
US6267976B1 (en) 2000-04-14 2001-07-31 Gojo Industries, Inc. Skin cleanser with photosensitive dye
US6800671B1 (en) 2000-04-21 2004-10-05 Britesmile, Inc. Low peak exotherm curable compositions
AU7262500A (en) 2000-09-14 2002-03-26 High Tech Laser Method and composition for dental bleaching
US6528555B1 (en) 2000-10-12 2003-03-04 3M Innovative Properties Company Adhesive for use in the oral environment having color-changing capabilities
DE10056114A1 (de) * 2000-11-04 2002-05-29 Wolfgang Malodobry Narbenfreie Entfernung von Tätowierungen
US6485709B2 (en) 2001-01-23 2002-11-26 Addent Inc. Dental bleaching gel composition, activator system and method for activating a dental bleaching gel
JP2002233612A (ja) 2001-02-07 2002-08-20 Daito Giken:Kk 遊技台
JP2002293747A (ja) * 2001-03-29 2002-10-09 Jinen:Kk 皮膚外用剤
EP1390084B1 (en) 2001-05-01 2011-03-23 A.V. Topchiev Institute of Petrochemical Synthesis Two-phase, water-absorbent bioadhesive composition
US6676816B2 (en) 2001-05-11 2004-01-13 Therasense, Inc. Transition metal complexes with (pyridyl)imidazole ligands and sensors using said complexes
ITMI20011315A1 (it) 2001-06-21 2002-12-21 Herbariorum Medicaminum Offici Composizione per pasta dentifricia antiplacca con rilevatore di placca
US20030009158A1 (en) 2001-07-09 2003-01-09 Perricone Nicholas V. Skin treatments using blue and violet light
US6558653B2 (en) 2001-09-19 2003-05-06 Scot N. Andersen Methods for treating periodontal disease
US7329273B2 (en) 2001-11-29 2008-02-12 Palomar Medicaltechnologies, Inc. Tissue penetrating oral phototherapy applicator
FR2833841B1 (fr) * 2001-12-21 2005-07-22 Galderma Res & Dev Gel comprenant au moins un retinoide et du peroxyde de benzoyle
EP1467760A2 (en) * 2002-01-23 2004-10-20 Light Sciences Corporation Systems and methods for photodynamic therapy
US7081128B2 (en) 2002-03-04 2006-07-25 Hart Barry M Phototherapy device and method of use
US6960079B2 (en) 2002-04-18 2005-11-01 3M Innovative Properties Company Orthodontic adhesives and appliances including an adhesive on the base of the appliance
AU2003273155A1 (en) 2002-05-07 2003-12-12 Atair Aerospace, Inc. Pneumatic riser release
US6949240B2 (en) 2002-05-23 2005-09-27 The Procter & Gamble Company Tooth whitening products
US7304201B2 (en) 2002-06-12 2007-12-04 University Of Florida Research Foundation, Inc. Phototherapy bandage
US6786274B2 (en) 2002-09-12 2004-09-07 York International Corporation Heat exchanger fin having canted lances
US20050098766A1 (en) 2002-09-19 2005-05-12 Watson David L.Jr. Chemiluminescent processes and systems
GB0222091D0 (en) 2002-09-24 2002-10-30 Boots Co Plc Dental compositions and methods
JP2006503080A (ja) 2002-10-11 2006-01-26 ノボセル インコーポレイテッド 疾患治療用のカプセルで包んだ生物材料の移植
CN1506042A (zh) * 2002-12-11 2004-06-23 苏加璐 使用来自胎儿细胞和组织的化合物改善皮肤状况的方法和组合物
WO2004061222A1 (en) 2003-01-02 2004-07-22 Metso Paper, Inc. Multiroll calender
US7157502B2 (en) 2003-02-19 2007-01-02 Pulpdent Corporation Polymerizable dental barrier material
WO2004081222A2 (en) 2003-03-14 2004-09-23 Sol-Gel Technologies Ltd. Agent-encapsulating micro- and nanoparticles, methods for preparation of same and products containing same
US20040191330A1 (en) * 2003-03-31 2004-09-30 Keefe Candace R. Daily skin care regimen
US7114953B1 (en) 2003-04-25 2006-10-03 Wagner Eugene C Tooth whitening appliance having membrane covered applicator
CN1835723B (zh) 2003-06-16 2011-06-22 洛马林达大学医学中心 可展开的多功能止血剂
JP2003339875A (ja) 2003-06-16 2003-12-02 Hirokatsu Kimura 入れ墨消去装置
GB0314210D0 (en) 2003-06-18 2003-07-23 Unilever Plc Laundry treatment compositions
KR100960687B1 (ko) 2003-06-24 2010-06-01 엘지디스플레이 주식회사 구리(또는 구리합금층)를 포함하는 이중금속층을 일괄식각하기위한 식각액
JP4219756B2 (ja) 2003-07-23 2009-02-04 京セラ株式会社 携帯端末装置
EA008771B1 (ru) 2003-07-31 2007-08-31 Сол-Джел Текнолоджиз Лтд. Микрокапсулы, заполненные активными ингредиентами, и способ их приготовления
WO2005032458A2 (en) 2003-08-01 2005-04-14 Glotell Products, Inc. Dye solution and method for detecting anhydrous ammonia
US8795693B2 (en) * 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US20050042712A1 (en) 2003-08-22 2005-02-24 Advanced Medical Optics, Inc. Methods, compositions and instruments to predict antimicrobial or preservative activity
US20050049228A1 (en) 2003-09-02 2005-03-03 Ceramoptec Industries Inc. Antimicrobial photodynamic therapy compound and method of use
US20050059731A1 (en) 2003-09-16 2005-03-17 Ceramoptec Industries, Inc. Erythrosin-based antimicrobial photodynamic therapy compound and its use
JP2007511616A (ja) * 2003-11-19 2007-05-10 バーンズ−ジューイッシュ ホスピタル 増強された薬物送達
US20070244195A1 (en) 2004-05-18 2007-10-18 Burkhart Craig N Treatment methods with peroxides and tertiary amines
CA2551613A1 (en) 2004-05-21 2005-12-01 Tottori University A composition comprising n-acetyl-d-glucosamine for treatment of wound
US20050281890A1 (en) 2004-06-18 2005-12-22 San Chandan K Methods and compositions for wound healing
US8465284B2 (en) 2004-07-08 2013-06-18 3M Innovative Properties Company Dental methods, compositions, and kits including acid-sensitive dyes
GB0420888D0 (en) * 2004-09-20 2004-10-20 Photopharmica Ltd Compounds and uses
CA2486475A1 (en) 2004-11-02 2006-05-02 John Kennedy Method of treating microorganisms in the oral cavity
EP1814509A2 (en) 2004-11-09 2007-08-08 Discus Dental Impressions, Inc. Dental whitening systems comprising transition metal salt activator
WO2006072243A1 (en) * 2005-01-03 2006-07-13 Novozymes Biopolymer A/S Hyaluronic acid fraction with moisturizing and anti-wrinkle properties
WO2006089028A2 (en) 2005-02-15 2006-08-24 Lab39, Llc Foaming compositions and methods
EP1733762A1 (en) 2005-05-25 2006-12-20 3M Espe AG Dental composition for detection of carious tissue, detection method
US20090285766A1 (en) * 2005-06-13 2009-11-19 National University Of Singapore Photosensitising Composition and Uses Thereof
WO2007001926A2 (en) * 2005-06-24 2007-01-04 Hyperbranch Medical Technology, Inc. Low-swelling hydrogel sealants for wound repair
EP1933941A2 (en) * 2005-08-25 2008-06-25 Philip R. Houle Treatment systems for delivery of sensitizer solutions
US8128973B2 (en) * 2005-09-07 2012-03-06 Noreen Mulvanerty Medicated skin care preparation for promoting wound healing
US20070092469A1 (en) * 2005-10-26 2007-04-26 Eric Jacobs Topically applied Glucosamine Sulfate and all its related, precursor, and derivative compounds significantly increases the skin's natural produciton of hyaluronic acid for the rejuvenation of healthier younger-looking skin; while PhosphatidylCholine is required to replace its deficiency caused by topical Dimethylaminoethanol (DMAE)
EP1779891A1 (en) * 2005-10-28 2007-05-02 Abdula Kurkayev Method of activating a photosensitizer
WO2007080453A2 (en) 2005-11-09 2007-07-19 Klox Technologies Inc. Teeth whitening compositions and methods
US8999933B2 (en) * 2006-01-18 2015-04-07 Biolitec Pharma Marketing Ltd Photodynamic cosmetic procedure and healing method
JP5117403B2 (ja) 2006-01-23 2013-01-16 ザ プロクター アンド ギャンブル カンパニー 酵素および光漂白剤を含む組成物
US8454991B2 (en) * 2006-07-24 2013-06-04 Quest Pharmatech Inc. Method and device for photodynamic therapy
EP2068622A4 (en) 2006-07-28 2012-10-10 Ceramoptec Gmbh METHOD AND MIXTURE FOR IN VIVO PHOTOCHEMICAL RETICULATION OF COLLAGEN
WO2008052081A2 (en) 2006-10-24 2008-05-02 California Institute Of Technology Photochemical therapy to affect mechanical and/or chemical properties of body tissue
US20080108681A1 (en) * 2006-10-27 2008-05-08 Access Business Group International Llc Use of allantoin as a pro-collagen synthesis agent in cosmetic compositions
US20100266989A1 (en) 2006-11-09 2010-10-21 Klox Technologies Inc. Teeth whitening compositions and methods
US20080113037A1 (en) * 2006-11-10 2008-05-15 Green Barbara A Topical Compositions Comprising Polyhydroxy Acids and/or Lactones for Improved Cutaneous Effects of Oxidative Therapeutic Drugs
JP2010514839A (ja) 2007-01-03 2010-05-06 バーナム インスティテュート フォー メディカル リサーチ クロット結合化合物に関連する方法および組成物
CN101677908A (zh) 2007-02-09 2010-03-24 科洛斯科技公司 用于牙龈隔离的光聚合材料
WO2009089345A2 (en) 2008-01-08 2009-07-16 Blazetrak, Llc Review managment system for audition portfolios
EP2231761A4 (en) 2008-01-08 2013-08-14 Quick Med Technologies Inc QUATERNARY AMMONIUM POLYMERS DISINFECTANTS SOLUBLE IN ALCOHOL
PL2352488T3 (pl) * 2008-11-07 2017-07-31 Klox Technologies Inc. Utleniająca, aktywowana światłem kompozycja do odmładzania skóry zawierająca kwas hialuronowy, glukozaminę lub alantoinę
HUE035716T2 (en) 2009-07-17 2018-05-28 Klox Tech Inc Antibacterial oral composition
WO2011058448A2 (en) 2009-10-27 2011-05-19 Klox Technologies Inc. Device for personal use in phototherapy
GB201012217D0 (en) 2010-07-21 2010-09-08 Republic Polytechnic Compounds for photodynamic therapy
US20130281913A1 (en) 2012-04-20 2013-10-24 Klox Technologies Inc. Biophotonic compositions and methods for providing biophotonic treatment
US8658466B2 (en) * 2012-06-18 2014-02-25 Chipbond Technology Corporation Semiconductor package structure and method for making the same
KR20210072827A (ko) 2012-09-14 2021-06-17 광동 클록스 바이오메디컬 그룹 씨오., 엘티디 생체 광자성 용도를 위한 발색단 조합
RU2015141708A (ru) 2013-03-01 2017-04-06 Клокс Текнолоджиз Инк. Фототерапевтическое устройство, способ и применение

Also Published As

Publication number Publication date
US8911791B2 (en) 2014-12-16
PL2365829T3 (pl) 2018-01-31
JP2012508189A (ja) 2012-04-05
KR101835047B1 (ko) 2018-03-08
PT3150210T (pt) 2019-09-04
HUE045950T2 (hu) 2020-01-28
JP2016006120A (ja) 2016-01-14
US8986745B2 (en) 2015-03-24
CA2936527A1 (en) 2010-05-14
CN104707143B (zh) 2018-04-27
JP5996077B2 (ja) 2016-09-21
SG10201703078QA (en) 2017-05-30
JP2017160277A (ja) 2017-09-14
CA2742942C (en) 2016-09-06
US8658219B2 (en) 2014-02-25
US9375446B2 (en) 2016-06-28
IL212560A (en) 2017-04-30
US10384072B2 (en) 2019-08-20
CN105640987A (zh) 2016-06-08
US20110224599A1 (en) 2011-09-15
DK2365829T3 (en) 2017-07-31
CY1119174T1 (el) 2018-02-14
JP2013253110A (ja) 2013-12-19
EA201792479A2 (ru) 2018-04-30
PT2352488T (pt) 2017-03-20
CN102300587B (zh) 2015-04-01
EA201792479A3 (ru) 2018-09-28
EP2365829B1 (en) 2017-05-24
EA029534B1 (ru) 2018-04-30
US20170049802A1 (en) 2017-02-23
DK3150210T3 (da) 2019-09-02
EP2352488B1 (en) 2017-01-04
LT2352488T (lt) 2017-05-25
EA201300898A1 (ru) 2014-04-30
JP2013253109A (ja) 2013-12-19
US8632822B2 (en) 2014-01-21
CA2742943A1 (en) 2010-05-14
WO2010051636A1 (en) 2010-05-14
HUE032192T2 (en) 2017-09-28
US20150306131A1 (en) 2015-10-29
US20190366113A1 (en) 2019-12-05
SI2365829T1 (sl) 2017-10-30
CA2742943C (en) 2016-09-13
AU2009311234B2 (en) 2013-05-02
LT2365829T (lt) 2017-10-25
US20190143137A1 (en) 2019-05-16
MX337084B (es) 2016-02-10
BRPI0920926A2 (pt) 2016-09-20
EP2365829A4 (en) 2011-10-19
NZ717641A (en) 2017-09-29
JP6166825B2 (ja) 2017-07-19
EP2365829A1 (en) 2011-09-21
EA201690702A1 (ru) 2016-11-30
CN105640987B (zh) 2020-04-14
DK2352488T3 (en) 2017-03-27
HRP20191416T1 (hr) 2019-11-15
US8974833B2 (en) 2015-03-10
HK1211478A1 (en) 2016-05-27
IL212559A (en) 2016-06-30
KR20110090983A (ko) 2011-08-10
US20130165845A1 (en) 2013-06-27
US20140221903A1 (en) 2014-08-07
CA2935819A1 (en) 2010-05-14
PL2352488T3 (pl) 2017-07-31
CN102256591B (zh) 2016-02-10
PT2365829T (pt) 2017-07-17
US20150065453A1 (en) 2015-03-05
ES2743314T3 (es) 2020-02-18
US20110218482A1 (en) 2011-09-08
MX339255B (es) 2016-05-18
CN102300587A (zh) 2011-12-28
KR20170141807A (ko) 2017-12-26
IL245427A0 (en) 2016-06-30
IL212559A0 (en) 2011-06-30
EA026962B1 (ru) 2017-06-30
IL212560A0 (en) 2011-06-30
SG10201703071YA (en) 2017-06-29
HK1225610A1 (zh) 2017-09-15
MX2011004865A (es) 2011-10-17
US10485986B2 (en) 2019-11-26
EP3150210A1 (en) 2017-04-05
JP2016020386A (ja) 2016-02-04
NZ592651A (en) 2013-05-31
KR20110094017A (ko) 2011-08-19
HRP20170343T1 (hr) 2017-06-16
CY1118716T1 (el) 2017-07-12
KR101717792B1 (ko) 2017-03-17
US10758744B2 (en) 2020-09-01
JP5996066B2 (ja) 2016-09-21
JP5478631B2 (ja) 2014-04-23
JP5478632B2 (ja) 2014-04-23
JP6167213B2 (ja) 2017-07-19
CA2936527C (en) 2022-05-17
PL3150210T3 (pl) 2019-12-31
SMT201700155T1 (it) 2017-05-08
JP5827654B2 (ja) 2015-12-02
US11020609B2 (en) 2021-06-01
KR20170031259A (ko) 2017-03-20
US20210283417A1 (en) 2021-09-16
EP3205355A1 (en) 2017-08-16
US8637086B2 (en) 2014-01-28
US9597349B2 (en) 2017-03-21
US20170143989A1 (en) 2017-05-25
EA024725B1 (ru) 2016-10-31
BRPI0920926B1 (pt) 2017-04-04
HRP20171022T1 (hr) 2017-09-22
NZ592650A (en) 2013-05-31
EA201170651A1 (ru) 2011-12-30
JP2016193951A (ja) 2016-11-17
WO2010051641A1 (en) 2010-05-14
EA201170650A1 (ru) 2011-12-30
EP2352488A4 (en) 2012-04-25
KR20180023070A (ko) 2018-03-06
JP2016193950A (ja) 2016-11-17
ES2632717T3 (es) 2017-09-15
JP5815622B2 (ja) 2015-11-17
EP3150210B1 (en) 2019-05-22
US20140221901A1 (en) 2014-08-07
MX2011004868A (es) 2011-10-17
JP2017160271A (ja) 2017-09-14
JP6453388B2 (ja) 2019-01-16
US20200330783A1 (en) 2020-10-22
NZ631218A (en) 2016-03-31
EP2352488A1 (en) 2011-08-10
MX376877B (es) 2025-03-07
US20140221902A1 (en) 2014-08-07
BRPI0921269A2 (pt) 2018-10-16
AU2009311239B2 (en) 2012-11-15
JP2012508190A (ja) 2012-04-05
IL251534A0 (en) 2017-05-29
SMT201700335T1 (it) 2017-09-07
AU2009311234A1 (en) 2010-05-14
NZ610404A (en) 2014-11-28
SI2352488T1 (sl) 2017-07-31
KR101810148B1 (ko) 2017-12-19
CN102256591A (zh) 2011-11-23
CN104707143A (zh) 2015-06-17
US11691025B2 (en) 2023-07-04
US10149985B2 (en) 2018-12-11
CA2742942A1 (en) 2010-05-14
AU2009311239A1 (en) 2010-05-14
EA024827B1 (ru) 2016-10-31

Similar Documents

Publication Publication Date Title
ES2618802T3 (es) Composición de rejuvenecimiento cutáneo fotoactivada oxidativa que comprende ácido hialurónico, glucosamina o alantoína
KR102067501B1 (ko) 광 펄스를 적용한 항균 드레싱 밴드
ES2244995T3 (es) Dispositivo para la irradiacion de luz sobre tejido.
RU2440835C2 (ru) Способ стимуляции роста волос и устройство для осуществления этого способа
ES2446490T3 (es) Temoporfina liposomal para uso en un método cosmético o terapéutico de regeneración y/o aumento de tejidos
de Paula Eduardo et al. Laser phototherapy in the treatment of periodontal disease. A review
US7084389B2 (en) Hand held led device
US20050080465A1 (en) Device and method for treatment of external surfaces of a body utilizing a light-emitting container
ES2709446T3 (es) Tratamiento fotodinámico por pulso del acné
Elavarasu et al. Lasers in periodontics
ES2871856T3 (es) Aparato y método para el tratamiento de la piel mediante el uso de luz pulsada
Shen et al. Neural regeneration in a novel nerve conduit across a large gap of the transected sciatic nerve in rats with low‐level laser phototherapy
Lima et al. Photobiomodulation via multiple-wavelength radiations
BR0115093A (pt) Sistema para tratar uma condição de um paciente e método de usar um sistema de tratamento de uma condição
JP2006519047A5 (es)
BR112015005382A2 (pt) combinações de cromóforos para utilizações biofotônicas, uso destes cromóforos, e kit
Ankri et al. Visible light induces no formation in sperm and endothelial cells
US20050065577A1 (en) Low level laser tissue treatment
Lubart et al. Biostimulative effects of low‐energy lasers and their implications for medicine
Garcia et al. Influence of low-level laser therapy on wound healing in nicotine-treated animals
JP2007504921A (ja) 光活性殺菌方法
Fekrazad et al. Photo biostimulatory effect of low dose photodynamic therapy on human mesenchymal stem cells
Faria et al. Effects of photodynamic process (PDP) in implant osseointegration: a histologic and histometric study in dogs
Hawkins et al. How long after laser irradiation should cellular responses be measured to determine the laser effect?
de Carvalho et al. Evaluation of laser phototherapy (λ 780 nm) after dental replantation in rats